MedMira (MedMira) Change In Receivables : $-0.10 Mil (TTM As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Change In Receivables?

MedMira's change in receivables for the quarter that ended in Jan. 2024 was $0.08 Mil. It means MedMira's Accounts Receivable declined by $0.08 Mil from Oct. 2023 to Jan. 2024 .

MedMira's change in receivables for the fiscal year that ended in Jul. 2023 was $-0.04 Mil. It means MedMira's Accounts Receivable increased by $0.04 Mil from Jul. 2022 to Jul. 2023 .

MedMira's Accounts Receivable for the quarter that ended in Jan. 2024 was $0.97 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. MedMira's Days Sales Outstanding for the three months ended in Jan. 2024 was 794.94.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MedMira's liquidation value for the three months ended in Jan. 2024 was $-13.87 Mil.

MedMira Change In Receivables Historical Data

The historical data trend for MedMira's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Change In Receivables Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Change In Receivables

Get a 7-Day Free Trial

0.03

-0.13

-0.83

-0.09

-0.04

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Receivables	Get a 7-Day Free Trial															0.07	-0.16	0.06	-0.09	0.08

MedMira Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

MedMira (OTCPK:MMIRF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

MedMira's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.967	/	0.111	*	91
=	794.94

2. In Ben Graham's calculation of liquidation value, MedMira's accounts receivable are only considered to be worth 75% of book value:

MedMira's liquidation value for the quarter that ended in Jan. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.636	-	15.307	+	0.75 * 0.967	+	0.5 * 0.158
=	-13.87

MedMira Change In Receivables Related Terms

Thank you for viewing the detailed overview of MedMira's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.